Welcome & introduction: Irene Ghobrial & Jesús San-Miguel

Keynote lecture #1: The best cancer is the cancer that never happens: Philip Castle

Plenary session #1: Early detection and screening – should we screen everyone or people at risk, germline risks?
Chairs: George Vassiliou & Jessica Okosun

• Origin of the precursor state in MM: Nikhil Munshi
• Germline predisposition in CLL: Susan Slager
• Germline predisposition to CH: Lucy Godley
• Genomic evolution from MGUS to MM: Francesco Maura

Panel discussion: Who should be screened for blood cancer precursors? Population research strategies

Break

Breakout Sessions #1

---

Multiple Myeloma/SMM/MGUS track
Chairs: Shaji Kumar & Felipe Prósper

• The iSTOPMM study – screening for MGUS: Sigurður Kristinsson
• Genetic susceptibility along the continuum from MGUS to MM: Celine Vachon
• The PROMISE study and other screening efforts so far: Elizabeth O’Donnell

Panel discussion: Designing early detection studies in MM

---

MDS/CHIP/AML/CCUS track
Chairs: George Vassiliou & Sanam Loghavi

• The evolution of clonal hematopoiesis to AML: Caroline Watson
• CH in stem cell transplant recipients: Coleman Lindsley
• Clonal selection of hematopoietic stem cells after transplantation: Michael Spencer Chapman
• The impact of chemotherapy on normal hematopoiesis: Emily Mitchell
• CHIP mutations in pre-leukemia vs. frank AML with focus on DNMT3A: Ravi Majeti

Panel discussion

---

Lymphoma/CLL track
Chairs: Tait Shanafelt & Julia Almeida

Role of MBL in the etiology of CLL

• Identification of specific genetic drivers of CLL long before diagnosis: Anton Langerak
• Charting the breeding ground of CLL: Hendrik Veelken

Lymphoma

• Genomic and transcriptomic characterization of MBL/CLL at the single cell level: Giovanni Tonon

Biology of precursor CLL and FL conditions

• Lymphoid clonal hematopoiesis and its relationship to monoclonal B-cell lymphocytosis: Aswin Sekar

Panel discussion

Welcome reception

Overview of Day 2

Keynote lecture #2: Global surveillance of carcinogen exposures using somatic mutations: Michael Stratton

Plenary session #2: Risk stratification and biomarkers – tumor, immune, non-immune marker, clinical (Part 1)
Chairs: Kelly Boulton & Bruno Paiva 

• Genomic evolution in MM: Rafael Fonseca
• Can we envisage immune biomarkers as tools for predicting risk of premalignant to malignant indolent lymphoma transition?: Stephen Ansell
• Utility of NGS to differentiate MN from other cytopenic conditions: Catherine Cargo
• Immune regulation in disease progression from MGUS to MM: Irene Ghobrial

Panel discussion: Defining what is a precancerous condition in blood cancers

Break

Plenary session #3: Risk stratification and biomarkers – tumor, immune, non-immune marker, clinical biomarkers (Part 2)
Chairs: Rafael Fonseca & Lucy Godley

• Minimally invasive tumor and immune-based stratification: Bruno Paiva
• Genetic ancestry and CH: George Vassiliou
• Mechanisms of disease progression from MBL to CLL: Paolo Ghia

Panel discussion: What is the risk of blood cancer precursors? Clinical tools for risk stratification

Technical break

Breakout sessions #2

---

Multiple Myeloma/SMM/MGUS track
Chairs: Nikhil Munshi & Kwee Yong

• Risk stratifying MGUS: Rafael Fonseca
• The evolution of risk stratification in smoldering myeloma: Shaji Kumar
• Circulating tumor cells and other novel biomarkers to be added to the current models: Romanos Sklavenitis-Pistofidis
• Biomarkers and imaging in precursor myeloma: Elena Zamagni
• Can epigenetics help us to understand the transition from MGUS to MM: Felipe Prósper

Panel discussion: Novel risk stratification

---

MDS/CHIP/AML/CCUS track
Chairs: Uma Borate

• Clonal Hematopoiesis in telomere and inflammatory disorders (CH in VEXAS syndrome): Mrinal Patnaik
• Prediction models in CH: Muxin Gu
• The role of TCL1A in promoting clonal hematopoietic disorders: Siddhartha Jaiswal
• Deconvoluting clonal and cellular architecture in IDH-mutant myeloid neoplasms: Iannis Aifantis
  

CH in specific contexts

• MN risk in sickle cell disease and other hereditary hemolytic anemias: Lachelle Weeks

Panel discussion

---

CLL/MBL/Lymphoma track
Chairs: Paolo Ghia & Jessica Okosun

• Tracing founder mutations/translocations – Should we be screening for lymphomas?: Sandrine Roulland
• Modelling early FL biology in murine models: Dinis Calado
• Bellinzona – ctDNA as a biomarker for predicting progression/screening in lymphoma: Davide Rossi

Lymphoma – biology of indolent to aggressive lymphomas

• FL to transformed FL – can we predict?: Jessica Okosun
• Other indolent entities (MZL) to DLBCL – what can we learn?: Silvia Beà
• Indolent to aggressive – progression of CLL to Richter transformation: Erin Parry

Panel discussion

Lunch

Keynote lecture #3: Interception – endpoints of trials, trial design, which patient population, diverse populations
Chairs: Matthew Davids & Elizabeth O’Donnell

FDA – endpoints and trial designs in precursor conditions: Nicole Gormley

Plenary session #4: Interception – endpoint of trials, which patient population, diverse populations (Part 1)
Chairs: Nikhil Munshi & Susan Slager

• The future of clinical trials and endpoints in early interception of myeloma: Kenneth Anderson
• Early intervention in SMM: Elizabeth O’Donnell
• Novel immune-therapeutics in SMM: Omar Nadeem
• Tools to predict early progression/clonal evolution to identify patients with B-cell malignancies for early intervention: Anna Schuh
• Early intervention approaches in CLL: Matthew Davids
• PIMMS study (decentralized trial of ivosidenib in CCUS): Kelly Bolton
• The utility of longitudinal clinical follow up in CHIP clinics – a 2024 update: Eric Padron

Panel discussion: Patient population considerations for blood cancer precursors and clinical trial design

Break

Breakout sessions #3

---

Multiple Myeloma/SMM/MGUS track
Chairs: Jesús San-Miguel & Elena Zamagni

• Non-drug approaches to intervention: Urvi Shah
• Characterizing risk and biology of SMM for early detection and intervention: Kwee Yong
• Prevention studies in MGUS and SMM: Catherine Marinac
• Endpoints for interception trials: Nikhil Munshi
• What is the ideal time to intervene in smoldering myeloma?: Shaji Kumar
• Therapy-related CH and multiple myeloma therapies: Adam Sperling

Panel discussion

---

MDS/CHIP/AML/CCUS track
Chairs: George Vassiliou & Eric Padron

• Decitabine/cedazuridine in high-risk CCUS: Maximilian Stahl
• Therapeutic vulnerabilities in CH: Siddhartha Kar
• Trials in CH – challenges and opportunities: Uma Borate
• Racial differences in outcomes from CH in multiple myeloma patients: Lachelle Weeks
• Updates on oral vitamin C for myeloid cancer patients: Kirsten Grønbæk

Panel discussion

---

CLL/MBL/Lymphoma track
Chairs: Sandrine Roulland & Anna Schuh

• MBL: Andrew Rawstron
• Early intervention in high-risk, asymptomatic CLL with acalabrutinib: Sameer Parikh
• PreVent-ACaLL trial and an overview of using machine-learning algorithms to assess risk of infection in CLL: Carsten Niemann
• CLL NeoVax trial update: Marwan Kwok & Inhye Ahn

Panel discussion

Faculty dinner

Overview of Day 3

Keynote session #4
Chairs: Irene Ghobrial & Uma Borate

• Vision of early interception, and barriers & opportunities for a cure: María-Victoria Mateos
• New approaches to tackling diversity challenges: Lachelle Weeks
• Early detection for high-risk cancer patients in Africa: Anna Schuh

Panel discussion

Plenary session #5: Workshop outcomes and initiatives – key outcomes and action item breakout sessions
Chairs: Julia Almeida & Rafael Fonseca

• Multiple Myeloma/SMM/MGUS: Shaji Kumar & Irene Ghobrial
• MDS/CHIP/AML/CCUS: George Vassiliou & Lachelle Weeks
• CLL/MBL/Lymphoma: Matthew Davids & Jessica Okosun

Panel discussion

Break

Plenary session #6: Stakeholder panel discussion
Chairs: Kenneth Anderson

Panellists: Jennifer Ahlstrom, Julia Colchie, Nicole Gormley, David Read, Karen Rodriguez Lorenc, Jeremy Ross, Craig Tendler, Helgi Van De Velde, Jeffrey Venstrom, Michael Yaffe

Summary and conclusion